# Williamson County

January Benefit Committee Meeting

**January 16, 2025** 



# Agenda


- Financials
  - Medical/Pharmacy Trend Review
- Large Claims Review
- January 2026 Plan Design Discussion
- Compliance Discussion
- Retiree Coverage Discussion
- Review Committee for Benefit RFPs


# **Financials**



### Financial – Medical Trend, Rolling 12


(before stop loss reimbursements)






### Financial – Medical Trend, PCL

### Past Coverage Level (PCL) - Medical



### Financial – Pharmacy Trend, Rolling 12

(before rebates)






### Financial – Pharmacy Trend, PCL

\$250

\$200



Oct-22 Dec-22 Feb-23 Apr-23 Jun-23

50th Percentile

Oct-23

Dec-23 Feb-24

25th Percentile

Actual


Aug-21 Oct-21 Dec-21 Feb-22 Apr-22 Jun-22 Aug-22

Past Coverage Level (PCL) - Rx

75th Percentile

### Financial – Dental Trend, Rolling 12








### Financial – Dental Trend, PCL

### Past Coverage Level (PCL) - Dental



# Large Claims

### Large Claims – CY2024, through 11/30/2024

					<u> </u>			i	
		Claimant	Medical						
	Relationship	Coverage	Diagnosis		RX Standard Therapeutic Class	*Derived Claim			
Claimant ID	Description	Status	Code	Medical Diagnosis Code Description	Description	Status	Medical Paid	Rx Paid	Total Paid
Claimant 1	EMPLOYEE	ACTIVE	G36.0	NEUROMYELITIS OPTICA	OTHER THERAPEUTIC CLASS	OPEN	\$435,251.41	\$146.39	\$435,397.80
Claimant 2	EMPLOYEE	ACTIVE	Z51.12	ENC ANTINEOPLASTIC IMMUNOTHERAPY	ANTINEOPLASTICS	OPEN	\$329,539.79	\$71,749.54	\$401,289.33
Claimant 3	EMPLOYEE	TERMED	182.210	ACUTE EMBO THROMBOSIS SUP VENA CAVA	ANTINEOPLASTICS	CLOSED	\$357,333.33	\$25,129.38	\$382,462.71
Claimant 4	CHILD	ACTIVE	J12.89	OTHER VIRAL PNEUMONIA	MISCELLANEOUS	OPEN	\$60,109.60	\$317,817.68	\$377,927.28
Claimant 5	SPOUSE	ACTIVE	Z51.12	ENC ANTINEOPLASTIC IMMUNOTHERAPY	MISCELLANEOUS	OPEN	\$303,451.31	\$59,738.17	\$363,189.48
Claimant 6	CHILD	ACTIVE	S32.82XA	MX FX PLV NO DIST PLV RING INIT CLS	OTHER THERAPEUTIC CLASS	OPEN	\$341,229.52	\$60.71	\$341,290.23
Claimant 7	EMPLOYEE	ACTIVE	N18.6	END STAGE RENAL DISEASE	ANTICOAGULANTS	OPEN	\$278,216.08	\$7,119.86	\$285,335.94
Claimant 8	SPOUSE	ACTIVE	Z51.12	ENC ANTINEOPLASTIC IMMUNOTHERAPY	ANTINEOPLASTICS	OPEN	\$52,568.43	\$217,379.06	\$269,947.49
Claimant 9	EMPLOYEE	TERMED	T84.226A	DISPLACEMENT IF DEVC VERTEBRAE INIT	LIPOTROPICS	CLOSED	\$248,837.58	\$289.14	\$249,126.72
Claimant 10	EMPLOYEE	ACTIVE	C79.51	SECONDARY MALIGNANT NEOPLASM BONE	ANTINEOPLASTICS	OPEN	\$53,492.89	\$193,829.18	\$247,322.07
Claimant 11	SPOUSE	ACTIVE	M48.07	SPINAL STENOSIS LUMBOSACRAL REGION	ANTIVIRALS	OPEN	\$237,834.37	\$1,664.62	\$239,498.99
Claimant 12	EMPLOYEE	ACTIVE	M48.061	SPINAL STENOSIS LUMBAR REGION NO NC	ANTICOAGULANTS	OPEN	\$232,847.93	\$4,221.43	\$237,069.36
Claimant 13	EMPLOYEE	ACTIVE	T82.856A	STENOSIS PERIPH VASCULAR STENT INIT	ANTICOAGULANTS	CLOSED	\$215,530.13	\$4,589.49	\$220,119.62
Claimant 14	EMPLOYEE	ACTIVE	S42.141A	DSPL FX GLND C SC RT SH INIT CLO FX	MISCELLANEOUS	OPEN	\$101,462.02	\$111,411.70	\$212,873.72
Claimant 15	EMPLOYEE	ACTIVE	Z51.0	ENCOUNTER ANTINEOPLSTC RADIATION TX	ANTINEOPLASTICS	OPEN	\$192,273.04	\$18,289.65	\$210,562.69
Claimant 16	EMPLOYEE	ACTIVE	Z51.12	ENC ANTINEOPLASTIC IMMUNOTHERAPY	DIABETIC THERAPY	OPEN	\$192,760.34	\$17,451.68	\$210,212.02
Claimant 17	CHILD	ACTIVE	S85.092A	OTH SPEC INJURY POP ART LT LEG INIT	ANTIDOTES	OPEN	\$198,517.88	\$109.32	\$198,627.20
Claimant 18	CHILD	ACTIVE	S52.502B	UNS FX LOW LT RADIUS INIT OPN I/II	OTHER THERAPEUTIC CLASS	OPEN	\$178,642.40	\$2,751.20	\$181,393.60
Claimant 19	SPOUSE	ACTIVE	G20.B2	PARK DZ W DYSKINESIA AND FLUCTUATN	ANTIPARKINSON	OPEN	\$103,421.32	\$53,065.08	\$156,486.40
Claimant 20	EMPLOYEE	ACTIVE	M48.02	SPINAL STENOSIS CERVICAL REGION	OTHER THERAPEUTIC CLASS	OPEN	\$149.394.20	\$1,479.64	\$150,873.84
Claimant 21	SPOUSE	ACTIVE	J10.1	FLU D/T OTH ID FLU VIR OTH RSP MANF	ANTIARTHRITICS	OPEN	\$7.995.62	\$137.421.68	\$145,417.30
Claimant 22	CHILD	ACTIVE	Z93.0	TRACHEOSTOMY STATUS	MISCELLANEOUS	OPEN	\$34,414.97	\$107,740.09	\$142,155.06
Claimant 23	CHILD	TERMED	999 999	OTHER DIAGNOSIS	OTHER ANTIBIOTICS	CLOSED	\$138.948.05	\$50.47	\$138,998.52
Claimant 24	CHILD	TERMED	Z38.01	SINGLE LIVEBORN INFANT DELIV C-SECT	ANTIFUNGALS	CLOSED	\$120,715.29	\$21.95	\$120,737.24
Claimant 25	SPOUSE	ACTIVE	T81.43XA	NFCT FL PRC ORG SPCE SRG SIT INIT	ESTROGENS	CLOSED	\$110,688.91	\$3.020.77	\$113,709.68
Cidilliant 25	SFOOSE	ACIIVE	10134322	INICITE FIC ONG SPCE SIG SIT INIT	ESTROGENS	CLOSED	\$110,000.51	\$3,020.11	\$115,705.00
Claimant 26	CHILD	ACTIVE	999.999	OTHER DIAGNOSIS	OTHER THERAPEUTIC CLASS	OPEN	\$112,686.73	\$608.91	\$113,295.64
Claimant 27	CHILD	ACTIVE	O32.1XX0	MATERNAL CARE BREECH PRES NA/UNS	MISCELLANEOUS	OPEN	\$27,844.72	\$85,083.50	\$112,928.22
Claimant 28	EMPLOYEE	ACTIVE	K50.00	CROHNS DISEASE SM INTEST W/O COMP	MISCELLANEOUS	OPEN	\$24,275.72	\$87,280.93	\$111,556.65
Claimant 29	CHILD	ACTIVE	999.999	OTHER DIAGNOSIS	GLUCOCORTICOIDS	OPEN	\$109,028.75	\$41.46	\$109,070.21
Claimant 30	CHILD	ACTIVE	999.999	OTHER DIAGNOSIS	ADRENERGICS	OPEN	\$106,284.97	\$1,379.86	\$107,664.83
Claimant 31	EMPLOYEE	ACTIVE	L40.50	ARTHROPATHIC PSORIASIS UNSPECIFIED	ANTIARTHRITICS	OPEN	\$919.57	\$102,841.01	\$103,760.58
Claimant 32	SPOUSE	ACTIVE	K56.600	PART INTESTINAL OBST UNS AS TO CAU	ALL OTHER DERMATOLOGICALS	CLOSED	\$47,183.20	\$55,583.33	\$102,766.53
Claimant 33	EMPLOYEE	ACTIVE	J02.0	STREPTOCOCCAL PHARYNGITIS	ALL OTHER DERMATOLOGICALS	OPEN	\$714.88	\$100.766.64	\$101.481.52
Cramilant 33	LIVITEOTEE	ACTIVE	302.0	STALL TOCOCCAE FINANTINGING	LE OTTEN DENVIATOLOGICALS	OFEIN	ş/ 14.00	\$100,766.64	\$101,401.32
Claimant 34	CHILD	ACTIVE	999.999	OTHER DIAGNOSIS	OTHER THERAPEUTIC CLASS	OPEN	\$100,404.70	\$798.54	\$101,203.24
Claimant 35	SPOUSE	ACTIVE	R31.9	HEMATURIA UNSPECIFIED	ALL OTHER DERMATOLOGICALS	OPEN	\$1,978.72	\$99,206.05	\$101,184.77
Countain 33	31 0032	ACTIVE	1(31.3	TERM TOTAL ONSTECHTED	LE OTTEN DENMATOROGICALS	OFEIN	\$1,310.12	<b>\$</b> 33,200.03	\$101,184.77
Claimant 36	EMPLOYEE	ACTIVE	S82.61XP	DSPL FX LM RT FIB SUB CLO MALUNION	OTHER THERAPEUTIC CLASS	OPEN	\$100,892.65	Page 157.92	\$100,900.57

## 2026 Plan Changes Discussion



### 2026 Plan Design Discussion

- Plan Design Discussion
  - Deductibles
  - Out-of-Pocket
  - Copays
  - Pharmacy Formulary
  - Network
  - Contributions

# **Compliance Discussion**



### Compliance Discussion

### **NQTL – Quantitative Treatment Limitations Analysis**

- To comply with this requirement, health insurance plans must provide a comparative analysis that demonstrates compliance with the requirements. This is to ensure equal access to care for mental health and substance use disorder (MH/SUD) compared to all other medical conditions.
- If the health insurance carrier or Third Party Administrator (TPA) isn't conducting the testing, it will be up to the plan fiduciary, the employer to either conduct the testing or engage a third party to conduct the testing.
- Holmes Murphy has third-party vendor partners we've used for NQTL analysis. The Cost of this analysis ranges from \$11,000 to \$15,000

### **Retiree Coverage Discussion**



### Retiree Coverage options

### What else should you consider?

Counties with 75,000 residents:

Sec. 175.002. RIGHT TO PURCHASE CONTINUED COVERAGE. Acts 1993, 73rd Leg.

Amended by: Acts 2009,

Sec. 175.003. LEVEL OF COVERAGE.

- (b) Same as when employment ended.
- (c) May substitute Medicare supplement health benefits coverage as the coverage.
- (d) The person may elect to continue coverage at a reduced level, if offered by the political subdivision.



### **Review Committee for Benefit RFPs**



### Review Committee for RFP

The County will need to market the following benefits for 2026:

- Group Life/AD&D Benefits
- Voluntary Life/AD&D Benefits
- Short Term Disability Benefits
- Long Term Disability Benefits

A review committee will be needed for the RFP specifications draft requirements and review of the proposals received.

# nank

